Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden. Use of causal modeling to uncover cell-cell communication dynamics in the tumor ...

A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic ...

The FDA accepted the BLA for ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer post-TKI ...

The regulation of cell death is fundamental to both organismal development and the maintenance of tissue homeostasis. Among the various modulators of cell death, Bax inhibitor proteins have emerged as ...

A Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center has reported that the novel ...

Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...

Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study. Completed ...

In an extensive review, researchers explore ZBP1-mediated programmed cell death and its potential as a therapeutic target for systemic diseases Programmed cell death, or PCD, is an actively regulated ...

In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes.

Cells that are about to die send a signal to an executioner protein, but sometimes, those cells can fight back and regenerate, becoming essentially a zombie cell.

BioWorld - Tuesday, March 11, 2025 Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review See today's BioWorld Science Home » Ilab patents new PD-1/PD-L1 interaction ...